Skip to main content
Erschienen in: International Urogynecology Journal 3/2017

18.08.2016 | Original Article

Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome?

verfasst von: Alexis M. Tran, Peter K. Sand, Miriam J. Seitz, Adam Gafni-Kane, Ying Zhou, Sylvia M. Botros

Erschienen in: International Urogynecology Journal | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

We compared persistence on overactive bladder (OAB) pharmacotherapy in patients treated in the Female Pelvic Medicine and Reconstructive Surgery (FPMRS) department compared with patients treated in the Internal Medicine (IM) and General Urology (GU) departments within an integrated health-care system. We hypothesized that persistence would be higher among FPMRS patients.

Methods

This was a retrospective cohort study. Patients with at least one prescription for OAB between January 2003 and July 2014 were identified. Demographic, prescription and treatment specialty data and data on the use of third-line therapies were collected. The primary outcome was persistence, defined as days on continuous pharmacotherapy. Discontinuation was defined as a treatment gap of ≥45 days. Discontinuation-free probabilities were calculated using the Kaplan-Meier method and compared among the specialties. Predictors of persistence were estimated using logistic regression with adjustment for covariates. Pearson correlation coefficients were calculated to identify risk associations.

Results

A total of 252 subjects were identified. At 12 weeks, 6 months and 1 year, FPMRS patients had the highest persistence rates of 93 %, 87 % and 79 % in contrast to 72 %, 68 % and 50 % in GU patients, and 83 %, 71 % and 63 % in IM patients (p = 0.006, p = 0.007, p = 0.001, respectively). The median persistence in FPMRS patients was 738 days, in GU patients 313 days and in IM patients 486 days (p = 0.006). Of the FPMRS patients, 61 % switched to at least a second medication, as compared to 27 % of IM patients and 14 % of GU patients (p < 0.0001).

Conclusions

Persistence on OAB pharmacotherapy was higher among FPMRS patients than among GU and IM patients in this community setting. These results suggest that persistence is higher under subspecialist supervision.
Literatur
1.
Zurück zum Zitat Basra RK, Wagg A, Chapple C, Cardozo L, Castro-Diaz D, Pons ME et al (2008) A review of adherence to drug therapy in patients with overactive bladder. BJU Int 102:774–779.CrossRefPubMed Basra RK, Wagg A, Chapple C, Cardozo L, Castro-Diaz D, Pons ME et al (2008) A review of adherence to drug therapy in patients with overactive bladder. BJU Int 102:774–779.CrossRefPubMed
2.
Zurück zum Zitat Stewart W, Rooyen JV, Cundiff F, Abrams P, Herzog AR, Corey R et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336.PubMed Stewart W, Rooyen JV, Cundiff F, Abrams P, Herzog AR, Corey R et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336.PubMed
3.
Zurück zum Zitat Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I (2011) National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 77(5):1081–1087.CrossRefPubMed Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I (2011) National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 77(5):1081–1087.CrossRefPubMed
4.
Zurück zum Zitat Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1315.CrossRefPubMed Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1315.CrossRefPubMed
5.
Zurück zum Zitat Cheung WW, Khan NH, Choi KK, Bluth MH, Vincent MT (2009) Prevalence, evaluation and management of overactive bladder in primary care. BMC Fam Pract 10:8.CrossRefPubMedPubMedCentral Cheung WW, Khan NH, Choi KK, Bluth MH, Vincent MT (2009) Prevalence, evaluation and management of overactive bladder in primary care. BMC Fam Pract 10:8.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Cheung WW, Borawski D, Abulafia O, Vincent MT, Harel M, Bluth MH (2011) Characterization of overactive bladder in women in a primary car setting. Open Access J Urol 3:29–34.PubMedPubMedCentral Cheung WW, Borawski D, Abulafia O, Vincent MT, Harel M, Bluth MH (2011) Characterization of overactive bladder in women in a primary car setting. Open Access J Urol 3:29–34.PubMedPubMedCentral
7.
Zurück zum Zitat Staskin DR, MacDiarmid SA (2006) Pharmacologic management of overactive bladder: practical options for the primary care physician. Am J Med 119(3 Suppl 1):24–8.CrossRefPubMed Staskin DR, MacDiarmid SA (2006) Pharmacologic management of overactive bladder: practical options for the primary care physician. Am J Med 119(3 Suppl 1):24–8.CrossRefPubMed
8.
Zurück zum Zitat Siu JY (2015) Communicating with mismatch and tension: treatment provision experiences of primary care doctors treating patients with overactive bladder in Hong Kong. BMC Fam Pract 16:160.CrossRefPubMedPubMedCentral Siu JY (2015) Communicating with mismatch and tension: treatment provision experiences of primary care doctors treating patients with overactive bladder in Hong Kong. BMC Fam Pract 16:160.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Jirschele K, Ross R, Goldberg G, Botros S (2015) Physician attitudes toward urinary incontinence identification. Female Pelvic Med Reconstr Surg 21(5):273–276.CrossRefPubMed Jirschele K, Ross R, Goldberg G, Botros S (2015) Physician attitudes toward urinary incontinence identification. Female Pelvic Med Reconstr Surg 21(5):273–276.CrossRefPubMed
10.
Zurück zum Zitat Finkelstein K, Glosner S, Sanchez RJ, Uddin N (2008) Prevalence of probable overactive bladder in private obstetrics and gynecology group practice. Curr Med Res Opin 24(4):1083–1090.CrossRefPubMed Finkelstein K, Glosner S, Sanchez RJ, Uddin N (2008) Prevalence of probable overactive bladder in private obstetrics and gynecology group practice. Curr Med Res Opin 24(4):1083–1090.CrossRefPubMed
11.
Zurück zum Zitat Nguyen K, Hunter K, Wagg A (2013) Knowledge and understanding of urinary incontinence: survey of family practitioners in northern Alberta. Can Fam Physician 59:e330–e337.PubMedPubMedCentral Nguyen K, Hunter K, Wagg A (2013) Knowledge and understanding of urinary incontinence: survey of family practitioners in northern Alberta. Can Fam Physician 59:e330–e337.PubMedPubMedCentral
12.
Zurück zum Zitat Rosenberg M, Witt ES, Barkin J, Miner M (2014) A practical primary care approach to overactive bladder. Can J Urol 31 Suppl 2:2–11. Rosenberg M, Witt ES, Barkin J, Miner M (2014) A practical primary care approach to overactive bladder. Can J Urol 31 Suppl 2:2–11.
13.
Zurück zum Zitat Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ et al (2012) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 188(6 Suppl):2455–2463.CrossRefPubMed Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ et al (2012) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 188(6 Suppl):2455–2463.CrossRefPubMed
14.
Zurück zum Zitat Kalder M, Pantazis K, Dinas K, Albert US, Heilmaier C, Kostev K (2014) Discontinuation and treatment using anticholinergic medications in patients with urinary incontinence. Obstet Gynecol 124:794–800.CrossRefPubMed Kalder M, Pantazis K, Dinas K, Albert US, Heilmaier C, Kostev K (2014) Discontinuation and treatment using anticholinergic medications in patients with urinary incontinence. Obstet Gynecol 124:794–800.CrossRefPubMed
15.
Zurück zum Zitat Malinar AS, Rejas J, Navarro-Artieda R, Aguado-Jodar A, Ruiz-Torrejon A, Ibanez-Nolla J et al (2014) Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis. Int Urogynecol J 25:485–492.CrossRef Malinar AS, Rejas J, Navarro-Artieda R, Aguado-Jodar A, Ruiz-Torrejon A, Ibanez-Nolla J et al (2014) Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis. Int Urogynecol J 25:485–492.CrossRef
16.
Zurück zum Zitat Kobelt G (1997) Economic considerations and outcome measurement in urge incontinence. Urology 50(6A Suppl):100–107.CrossRefPubMed Kobelt G (1997) Economic considerations and outcome measurement in urge incontinence. Urology 50(6A Suppl):100–107.CrossRefPubMed
17.
Zurück zum Zitat Wagg A, Compion G, Fahey A, Siddiquui E (2012) Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 110:1767–1774.CrossRefPubMed Wagg A, Compion G, Fahey A, Siddiquui E (2012) Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 110:1767–1774.CrossRefPubMed
18.
Zurück zum Zitat Sexton CC, Notte S, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D et al (2011) Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systemic review of the literature. Int J Clin Pract 65:567–585.CrossRefPubMed Sexton CC, Notte S, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D et al (2011) Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systemic review of the literature. Int J Clin Pract 65:567–585.CrossRefPubMed
19.
Zurück zum Zitat Chancellor MB, Migliaccio-Walle K, Bramley T, Chaudhari SL, Corbell C, Globe D (2013) Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther 25:1744–1751.CrossRef Chancellor MB, Migliaccio-Walle K, Bramley T, Chaudhari SL, Corbell C, Globe D (2013) Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther 25:1744–1751.CrossRef
20.
Zurück zum Zitat Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z (2005) Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 11:S121–S129.PubMed Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z (2005) Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 11:S121–S129.PubMed
21.
Zurück zum Zitat Yu TF, Nichol MB, Yu AP, Ahn J (2005) Persistence and adherence of medication for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 8:495–504.CrossRefPubMed Yu TF, Nichol MB, Yu AP, Ahn J (2005) Persistence and adherence of medication for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 8:495–504.CrossRefPubMed
22.
Zurück zum Zitat Echols K, Verma U, Policaro F, Medina CA (2000) Idiopathic hyperactivity and ditropan: an efficacy and compliance issue. Obstet Gynecol 95(4 Suppl 1):S24.CrossRef Echols K, Verma U, Policaro F, Medina CA (2000) Idiopathic hyperactivity and ditropan: an efficacy and compliance issue. Obstet Gynecol 95(4 Suppl 1):S24.CrossRef
23.
Zurück zum Zitat Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A medium-term analysis of the subjective efficacy of treatment of women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104:988–993.CrossRefPubMed Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A medium-term analysis of the subjective efficacy of treatment of women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104:988–993.CrossRefPubMed
24.
Zurück zum Zitat Visco AG, Brubaker L, Jelovsek E, Wilson TS, Norton P, Zyczynski HM et al (2016) Adherence to oral therapy for urgency urinary incontinence: results from the Anticholinergic versus Botox Comparison (ABC) trial. Female Pelvic Med Reconstr Surg 22:24–28.CrossRefPubMedPubMedCentral Visco AG, Brubaker L, Jelovsek E, Wilson TS, Norton P, Zyczynski HM et al (2016) Adherence to oral therapy for urgency urinary incontinence: results from the Anticholinergic versus Botox Comparison (ABC) trial. Female Pelvic Med Reconstr Surg 22:24–28.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Johnston BJ (2013) The role of patient experience and its influence on adherence to anti-depressant treatment. J Psychosoc Nurs Ment Health Serv 51(12):29–37.CrossRefPubMed Johnston BJ (2013) The role of patient experience and its influence on adherence to anti-depressant treatment. J Psychosoc Nurs Ment Health Serv 51(12):29–37.CrossRefPubMed
27.
Zurück zum Zitat Smith AL, Nissim HA, Le TX, Khan A, Maliski SL, Litwin MS et al (2011) Misconceptions and miscommunication among aging women with overactive bladder symptoms. Urology 77(1):55–59.CrossRefPubMed Smith AL, Nissim HA, Le TX, Khan A, Maliski SL, Litwin MS et al (2011) Misconceptions and miscommunication among aging women with overactive bladder symptoms. Urology 77(1):55–59.CrossRefPubMed
28.
Zurück zum Zitat Grimes D (2010) Epidemiologic research using administrative databases. Obstet Gynecol 116:1018–1019.CrossRefPubMed Grimes D (2010) Epidemiologic research using administrative databases. Obstet Gynecol 116:1018–1019.CrossRefPubMed
29.
Zurück zum Zitat Yeaw J, Benner JS, Walt JG, Siams S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15:728–740.PubMed Yeaw J, Benner JS, Walt JG, Siams S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15:728–740.PubMed
Metadaten
Titel
Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome?
verfasst von
Alexis M. Tran
Peter K. Sand
Miriam J. Seitz
Adam Gafni-Kane
Ying Zhou
Sylvia M. Botros
Publikationsdatum
18.08.2016
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 3/2017
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-016-3118-1

Weitere Artikel der Ausgabe 3/2017

International Urogynecology Journal 3/2017 Zur Ausgabe

Urogynecology Digest

Urogynecology digest

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Welche Übungen helfen gegen Diastase recti abdominis?

30.04.2024 Schwangerenvorsorge Nachrichten

Die Autorinnen und Autoren einer aktuellen Studie aus Griechenland sind sich einig, dass Bewegungstherapie, einschließlich Übungen zur Stärkung der Bauchmuskulatur und zur Stabilisierung des Rumpfes, eine Diastase recti abdominis postpartum wirksam reduzieren kann. Doch vieles ist noch nicht eindeutig belegt.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.